3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Sarcoma
4
Neoplasms
4
Neoplasm Metastasis
4
Hematologic Neoplasms
4
Breast Neoplasms
4
Brain Neoplasms
4
Pancreatic Neoplasms
3
Melanoma
3
Glioma
3
Thyroid Cancer, Papillary
2
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Leukemia, Myeloid, Acute
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Uveal Melanoma
1
Thrombocytosis
1
Solid Tumors
1
Solid Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Rare Tumour
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Noonan Syndrome 6
1
Interventions
Gemcitabine
111
Cisplatin
75
Oxaliplatin
43
pembrolizumab
34
Fluorouracil
31
Capecitabine
30
durvalumab
26
Leucovorin
25
lenvatinib
23
Magnetic Resonance Spectroscopy
14
Irinotecan
13
Nivolumab
12
Albumin-Bound Paclitaxel
12
Specimen Handling
11
Radiofrequency Ablation
11
Drug Therapy
11
Biopsy
11
tislelizumab
10
pemigatinib
10
apatinib
10
Taxes
10
Floxuridine
10
130-nm albumin-bound paclitaxel
10
Radiotherapy
9
Bevacizumab
9
Folfox protocol
8
Carboplatin
8
tremelimumab
7
atezolizumab
7
S 1 (combination)
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Cholangiocarcinoma
×
entrectinib
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA